CHEST 2025: Respiratory Virus Vaccines & Uptake
- Understanding the nuances of influenza, RSV, and emerging mRNA vaccine technologies.
- For decades, developing an effective RSV (Respiratory Syncytial Virus) vaccine proved challenging.
- Pre-fusion vaccines stabilize the virus in a specific conformation, eliciting a more robust and protective immune response.
“`html
Table of Contents
Understanding the nuances of influenza, RSV, and emerging mRNA vaccine technologies.
The Evolution of RSV Vaccination
For decades, developing an effective RSV (Respiratory Syncytial Virus) vaccine proved challenging. Early vaccine candidates, surprisingly, demonstrated worse outcomes in vaccinated individuals, halting progress for a critically important period.according to Dr. Kristina Crothers, a professor at the university of Washington in Pulmonary, Critical Care, and Sleep Medicine, the breakthrough came with the development of pre-fusion RSV vaccines. Pharmacy Times interview with Kristina Crothers, MD
Pre-fusion vaccines stabilize the virus in a specific conformation, eliciting a more robust and protective immune response. This has led to the approval and availability of RSV vaccines, marking a significant milestone in preventing severe respiratory illness, especially in infants and older adults.
Influenza Vaccine Advancements
While influenza vaccines are routinely updated to address circulating strains, recent advancements are focusing on improving vaccine efficacy and broadening protection. Dr. Crothers highlights two key developments: higher-dose and adjuvanted influenza vaccines. these vaccines are designed to stimulate a stronger immune response, particularly in older adults whose immune systems may be less responsive to standard-dose vaccines.
Furthermore, research is actively underway to develop mRNA influenza vaccines. This technology, successfully utilized in COVID-19 vaccines, holds the potential for faster development cycles and improved matching to circulating strains. While not yet in widespread use,mRNA influenza vaccines represent a promising future direction for influenza prevention.
| Vaccine Type | Mechanism | Target Population |
|---|---|---|
| High-Dose Influenza | Contains a higher dose of antigen to stimulate a stronger immune response. | Adults 65 years and older |
| Adjuvanted Influenza | Includes an adjuvant to enhance the immune response. | Adults 65 years and older |
| mRNA Influenza (in development) | Utilizes mRNA technology to deliver genetic instructions for producing viral proteins. | All ages (potential) |
Individual Vaccine Considerations
As the opening statement emphasizes, acceptance of one vaccine doesn’t guarantee acceptance of another. Individual attitudes towards vaccines are complex and influenced by a variety of factors, including personal beliefs, prior experiences, and perceived risk.